People with a demyelinating disease associated with antibodies against a myelin oligodendrocyte glycoprotein (MOG), most often develop episodes of optic neuritis (inflammation of the optic nerve) that can ... Read more
Mavenclad reduced multiple sclerosis relapses by 79 percent and prevented the development of additional inflammatory lesions in 84 percent of patients with high disease activity, according ... Read more
Genentech will present a host of new information on its multiple sclerosis treatment Ocrevus and lessons its scientists have learned about the disease at the 7th Joint ECTRIMS-ACTRIMS Meeting ... Read more
Gilenya decreased relapses in children and adolescents with multiple sclerosis in the phase 3 PARADIGMS trial, according to the therapy’s developer, Novartis.
The Swiss company will present ... Read more
MediciNova will present data from its clinical trial of ibudilast in progressive multiple sclerosis at the upcoming 7th Joint ECTRIMS – ACTRIMS Meeting in Paris.
ECTRIMS and ... Read more
Pin It on Pinterest